Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome.
Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia
in patients with myelodysplastic syndrome.
PURPOSE: Phase II trial to study the effectiveness of amifostine with or without epoetin alfa
in treating patients who have myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC